TRPV2
ENSG00000187688
Target class
Ion channel
Chromosome
17
- Chemical probe available
- No
- Target name
- TRPV2
- Gene name
- Transient receptor potential cation channel subfamily V member 2
- Gene symbol
- TRPV2
- Protein name
- Transient receptor potential cation channel subfamily V member 2 (TrpV2) (Osm-9-like TRP channel 2) (OTRPC2) (Vanilloid receptor-like protein 1) (VRL-1)
- VRL
- VRL-1
- VRL1
- Gene biotype
- Protein coding
- Gene family
- Transient receptor potential cation channels|Ankyrin repeat domain containing
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 83.47
- Tissue specificity (Gini)
- 0.505
- Tissue specificity (tau)
- 0.85
- KEGG gene identifiers
- hsa:51393
- Reactome pathways
- R-HSA-3295583
- Protein interaction confidence
- 0.835133
- Protein interaction partners
- 15
- End position
- 16437003
- Start position
- 16415571
- Chromosome
- 17
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein . Cytoplasm . Melanosome . Note=Translocates from the cytoplasm to the plasma membrane upon ligand stimulation (By similarity). Expressed in melanosomes during melanosome maturation from stage I to stage IV. .
- Plasma membrane
Publication evidence
- PubMed 17081065
- Tissue specificity (tau)
- 0.849904
- Expression inequality (Gini)
- 0.505436
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 83.47
- Lung
- 61.57
- Spleen
- 43.16
- Artery - Coronary
- 36.19
- Artery - Tibial
- 33.82
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes83.47
- Lung61.57
- Spleen43.16
- Artery - Coronary36.19
- Artery - Tibial33.82
- Whole Blood31.56
- Cells - Cultured fibroblasts29.84
- Adipose - Visceral (Omentum)25.55
- Adrenal Gland24.94
- Adipose - Subcutaneous23.97
- Ovary17.57
- Small Intestine - Terminal Ileum17.28
- Bladder16.35
- Breast - Mammary Tissue15.89
- Nerve - Tibial15.53
- Uterus15.25
- Fallopian Tube15.24
- Cervix - Endocervix15.09
- Cervix - Ectocervix14.82
- Artery - Aorta14.34
- Vagina13.98
- Thyroid13.54
- Esophagus - Gastroesophageal Junction12.74
- Esophagus - Muscularis12.65
- Prostate10.72
And 29 more, listed on the interactive page.
- GO:0007600
- GO:0009266
- GO:0070588
Cellular components
- GO:0005886
- GO:0005216
- GO:0005261
- GO:0005262
- GO:0005515
- GO:0015075
Related records
Trials (440)
- 5-Way Crossover Study to Compare the Safety, Tolerability and Pharmacokinetics of New Oral Cannabinoid Formulations Administered as Single Doses, With Buccal Sativex®, in Healthy Volunteers
- A Clinical Study of Tranilast in the Treatment of Cryopyrin-Associated Periodic Syndrome (CAPS)
- A Clinical Study of Tranilast in the Treatment of Mucinoses
- A Clinical Study of Tranilast in the Treatment of Sarcoidosis
- A Clinical Study of Tranilast in the Treatment of Scleredema Diabeticorum
- A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
- A Clinical Trial on the Antipsychotic Properties of Cannabidiol
- A Crossover Pilot Study of the Effect of Amiloride on Proteinuria
- A Double-Blind Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory Epilepsy
- A Double-Blinded Study on Rapid and Sustained Pain Relief Topical Cannabidiol for Plantar Fasciitis
- A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients
- A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
- A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects
- A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects
- A New Application of Amiloride in the Treatment of Patient With Chronic Kidney Disease In Reducing Urinary PROtein
- A Pharmacokinetic Study to Compare CBD-NE to Epidyolex in Healthy Adult Volunteers Under Both Fed and Fasted Conditions
- A Phase 2a Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis
- A Phase I Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers
- A Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis (GWID10160)
- A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
Drugs (5)
- Amiloride
- Cannabidiol
- Loratadine
- SK&F-96365
- Tranilast